Tvardi Therapeutics, Inc. TVRD
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 24.53% | -- | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.40% | -- | -- | -- | -- |
| Operating Income | 8.40% | -- | -- | -- | -- |
| Income Before Tax | -10.29% | -- | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.29% | -- | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.29% | -- | -- | -- | -- |
| EBIT | 8.40% | -- | -- | -- | -- |
| EBITDA | 8.43% | -- | -- | -- | -- |
| EPS Basic | 73.00% | -- | -- | -- | -- |
| Normalized Basic EPS | 73.00% | -- | -- | -- | -- |
| EPS Diluted | 76.44% | -- | -- | -- | -- |
| Normalized Diluted EPS | 73.03% | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 134.92% | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 131.89% | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |